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Background: Postnatal transmission of HIV-1 through breast milk remains an unsolved challenge in many
resource-poor settings where replacement feeding is not a safe alternative. WHO now recommends breastfeeding
of infants born to HIV-infected mothers until 12 months of age, with either maternal highly active antiretroviral
therapy (HAART) or peri-exposure prophylaxis (PEP) in infants using nevirapine. As PEP, lamivudine showed a similar
efficacy and safety as nevirapine, but with an expected lower rate of resistant HIV strains emerging in infants who
fail PEP, and lower restrictions for future HIV treatment. Lopinavir/ritonavir (LPV/r) is an attractive PEP candidate with
presumably higher efficacy against HIV than nevirapine or lamivudine, and a higher genetic barrier to resistance
selection. It showed an acceptable safety profile for the treatment of very young HIV-infected infants. The ANRS
12174 study aims to compare the risk of HIV-1 transmission during and safety of prolonged infant PEP with LPV/r
(40/10 mg twice daily if 2-4 kg and 80/20 mg twice daily if >4 kg) versus Lamivudine (7,5 mg twice daily if 2-4 kg,
25 mg twice daily if 4-8 kg and 50 mg twice daily if >8 kg) from day 7 until one week after cessation of BF
(maximum 50 weeks of prophylaxis) to prevent postnatal HIV-1 acquisition between 7 days and 50 weeks of age.
Methods: The ANRS 12174 study is a multinational, randomised controlled clinical trial conducted on 1,500
mother-infant pairs in Burkina Faso, South Africa, Uganda and Zambia. We will recommend exclusive breastfeeding
(EBF) until 26th week of life and cessation of breastfeeding at a maximum of 49 weeks in both trial arms.
HIV-uninfected infants at day 7 (± 2 days) born to HIV-1 infected mothers not eligible for HAART who choose to
breastfeed their infants.
The primary endpoint is the acquisition of HIV-1 (as assessed by HIV-1 DNA PCR) between day 7 and 50 weeks of
age. Secondary endpoints are safety (including resistance, adverse events and growth) until 50 weeks and
HIV-1-free survival until 50 weeks.
Discussion: This study will provide a new evidence-based intervention to support HIV-1-infected women not
eligible for HAART to safely breastfeed their babies.
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Out of the 420,000 annual new paediatric infections of
HIV-1, more than 200,000 are a result of breast milk
transmission, almost exclusively in developing countries.
By pooling data from five observational studies, the
estimated additional risk of transmission attributable to
breastfeeding is 14% (95% CI: 7-22%) [1]. In recent years,
observational studies including prospective cohorts have
shown that exclusive breastfeeding (EBF) is associated
with a reduced risk of HIV-1 transmission as compared
to mixed feeding [2-5].
Postnatal transmission of HIV-1 through breast milk
remains an unsolved challenge in many resource-poor
settings. In Sub-Saharan Africa, especially in the rural
areas, replacement feeding has proven a problematic
alternative to breastfeeding because of social, cultural,
economic and hygienic constraints [6]. Moreover, exclu-
sively or predominantly breastfed infants are likely to
have a substantially lower risk of succumbing to com-
mon childhood infections such as diarrhoea and pneu-
monia [7,8] that also inflict a substantial nutritional
insult. Therefore, strategies that both prevent MTCT
and allow for optimal breastfeeding are urgently needed.
One option is to reduce the infectivity of the mothers
during the breastfeeding period. The recently completed
“Kesho Bora” randomised controlled trial showed that
HIV transmission risk using maternal HAART from 28–
36 weeks pregnancy until 6 months after birth was 4.9%
(95%CI: 3.1-7.6) vs. 8.4% (95%CI:6.0-11.6) using a short
course ART (standard PMTCT) [9]. Another study
in Botswana reported even lower transmission risks at
6 months using two different HAART regimens (2%
and 1%) [10].
Another option is to give infants a prophylaxis during
the breastfeeding period (peri-exposure prophylaxis-
PEP). The advantages of PEP compared with maternal
HAART are that: ART drug prophylaxis in an uninfected
child carries no risk of selection of resistant viral strains;
it may be more acceptable and applicable; it carries a
lower cost and it spares mothers from using HAART at
a stage of disease when its benefits have not been
demonstrated, thereby avoiding HAART side effects and
selection of resistant viral strains.
Several studies concurred to prove the concept that
PEP can prevent postnatal transmission, using either
nevirapine (NVP) or lamivudine (3TC) and various dura-
tions of PEP (Table 1). The risks of postnatal transmis-
sion of HIV at 6 months with PEP ranges from 1.2%
using 3TC (95%CI: 0–2.4, among infants not infected
with HIV at 6 weeks) to 1.8% using NVP (among infants
not infected with HIV at one week). This strategy proved
very efficacious during the period of prophylaxis, but
this effect faded off after drug withdrawal as the HIV
exposure continued [11,12]. All the studies used PEP fora maximum of 6 months while many HIV-infected
women continued to breastfeed until 12 months.
Tolerance of extended NVP was acceptable although
15% of babies experienced NVP-related side effects,
while no drug-related severe adverse events were
reported with 3TC [13]. Major concerns arose from a
sub-study of SWEN in India which reported that 92% of
babies infected despite NVP prophylaxis harboured
viruses resistant to NVP, thus jeopardizing the use of
any drug of this therapeutic class (NNRTI) for future
treatment of these infants, which restricts considerably
the number of ART drugs available in low-income coun-
tries. These data were expected as NVP has a low
genetic barrier and is therefore very prone to select
resistant strains.
Based on the results of the above studies, WHO
recommends to use either maternal HAART or NVP
during breastfeeding to prevent postnatal HIV transmis-
sion [14]. In addition, breastfeeding is recommended
until 12 months to reduce the increased morbidity and
mortality related to early weaning. However, the PEP
strategy has never been evaluated for the whole duration
of breastfeeding.
The choice of the ideal drug for PEP should result
from a balance between efficacy, safety and resistance
induced among infants who will fail. In this respect, we
believe that 3TC is a better drug than NVP for PEP as it
has a better safety profile (including clinical consequence
of resistance in infected babies) and a presumably
similar efficacy [15,16].
Very recent findings suggest that Lopinavir/Ritonavir
(LPV/r), with its paediatric formulation, may be a very
good candidate for HIV-1 PEP. LPV/r is one of the
most potent antiretroviral drugs, with a much higher
anti-HIV-1 activity than 3TC or NVP [17]. In addition,
its high genetic barrier makes the development of LPV
resistant strains very unlikely. Despite these very promis-
ing features for HIV prophylaxis, LPV/r was not initially
considered for PEP because no safety data were reported
in young infants. However, recent data suggest a good
safety profile. In the CHER trial, 252 HIV-1 infected
infants aged 6 to 12 weeks (median 7.2 weeks) received
a combination therapy including LPV/r (300/75 mg per
m2 bid until 6 months of age, then 230/57 mg per m2
bid), Zidovudine and Lamivudine [18]. During the 40-
week follow-up, neutropaenia occurred in 10 children,
anemia in three, and elevated aminotransferase levels
in two. Four children switched from Zidovudine to
Stavudine because of neutropaenia. LPV/r was not
discontinued in any child and no severe adverse event
was related to this drug.
A smaller cohort of 21 infants aged 7 to 26 weeks trea-
ted with LPV/r (300/75 mg/m2 twice daily) plus 2 NRTI
confirmed these encouraging findings [19]. Tolerance
Table 1 Number of events and sample size according to potential efficacy rates in both arms
HIV transmission in 3TC arm
0.03 0.04 0.05
HIV transmission in LPV/r arm 0.01 1428 subjects 682 subjects 430 subjects
27 events 16 events 12 events
0.015 3190 subjects 1223 subjects 704 subjects
67 events 32 events 22 events
0.02 2204 subjects 1118 subjects
63 events 37 events
0.025 1800 subjects
64 events
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three children possibly related to HAART: asymptomatic
serum/sodium disturbances in two infants that resolved
with disruption of therapy for 0–2 weeks and did not
recur thereafter, and alanine aminotransferase elevation
that did not recur after treatment suspension for 3 days.
Some minor cholesterol disturbances were recorded in
eight infants. Finally, a pharmacokinetic and safety study
among 10 perinatally infected infants aged 3 to 6 weeks
was recently reported. Adverse events were limited to
transient grade 3 neutropaenia in three subjects (2 likely
related to NRTI drugs and 1 temporally related to high
plasma levels of LPV/r and stabilised after restarting
LPV/r at reduced dose (the dose we will use for our
trial). However, one fatal case of overdosage was
recorded in France (Lyon) where a young infant died
after absorption of a 10-fold higher dose than recom-
mended at his age (S. Blanche, personal communica-
tion). Therefore, cautions should be taken to educate
mothers and avoid massive overdosage.
The same studies by Chadwick and coll. also provided
pharmacological data on LPV/r in infants [20]. Briefly,
the bioavailability of LPV/r is reduced in young infants
and therefore there is a need to adapt dosing per kg
throughout the first year of life. These data were con-
firmed by a French pharmacokinetic study among 66
neonates who received LPV/r to prevent late perinatal
HIV transmission. A dosage regimen of LPV 15 mg/kg
bid was recommended for this age-group to achieve
therapeutic levels [21].
The primary objective of the study is to compare the
HIV-1 transmission risk between 7 days and 50 weeks of
age when infants are given LPV/r (40/10 mg twice daily
if 2-4 kg and 80/20 mg twice daily if >4 kg) or lamivu-
dine (12 mg twice daily if <6 kg, 24 mg per day if 6.0 to
9.0 kg, and 36 mg per day if ≥ 9.0 kg) from day 7 until
one week after cessation of BF (maximum duration of
prophylaxis: 50 weeks).
Secondary objectives are i) to assess the safety of long-
term infant prophylaxis with LPV/r versus lamivudine
(including resistance, adverse events and infant growth)until 50 weeks, ii) HIV-1-free survival until 50 weeks
and iii) to build clinical trials capacity at the four
study sites.Methods
Study design
We designed a multicentre randomised controlled prag-
matic trial. Although double blinding is not implemen-
ted for this study, we will mask drug bottles with study
labels and keep study physicians in charge of study
visits and adverse events collection, and staff in charge
of anthropometric measurements unaware of treatment
allocation. In addition, biologists in charge of infant HIV
diagnosis (primary outcome) will be blinded.
We here describe the version 3.0 of the study protocol,
registered at www.clinicaltrials.gov (NCT00640263).
All women who agree to participate in the study will
be counselled to exclusively breastfeed their babies up
to 6 months of age, and to gradually introduce comple-
mentary food thereafter and to stop breastfeeding at
49 weeks. This will give women sufficient time to pre-
pare for cessation of breastfeeding. Continuous counsel-
ling on a nutritionally balanced diet will be made
available up to 50 weeks of age. In order to cover the
whole breastfeeding period, the maximum duration of
prophylaxis is 50 weeks. The infants will be tested for
HIV-1 at Birth, Day 7, Week 6, 14, 26, 38 and 50
(Figure 1).Participants
Infants will be recruited and followed in Ouagadougou
(Burkina Faso), East London (South Africa), Mbale
(Uganda) and Lusaka (Zambia). HIV-infected pregnant
women will be identified at antenatal clinics. Breastfed
infants of HAART-treated mothers ingest sufficient
amounts of ART in milk to reach plasma therapeutic
levels (at least for NVP, LPV/r, AZT and 3TC) [22].
Therefore, in order to avoid overdosage of LPV/r and
Lamivudine in babies, our trial will only recruit babies
born to mothers that are not eligible for HAART
National care 
Birth 
Country  
specific 
PMTCT 
PEP trial 
3TC vs. LPV/r 
Scheduled visits 
Country specific PMTCT Maternal medication 
Infant medication 
Infant HIV-1 PCR 
Infant trial: Day 7– Week 50  
Counselling on exclusive breastfeeding (EBF) Partial breastfeeding / 
cessation 
w10 w6 w14 w18 w22 w26 w30 w34 w38 w42 w46 w50 
Drugs if BF 
w28 Day 7 
Randomisation 
w2 
Feeding counselling 
Figure 1 ANRS 12174 PROMISE-PEP trial design including scheduled follow-up visits.
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cells/μL blood.
A baby will be included if she/he:
 is a singleton
 is breastfed at day 7 by her/his mother and her/his
mother intends to continue breastfeeding for at
least 6 months
 has a post-partum blood sample with a negative
HIV-1 DNA PCR test result at day 7 (+/− 2 days)
 has received some antiretroviral prophylaxis at
birth or during the first week
 if the mother:has reached the local legal age for participating in
medical research studies
is HIV-1 infected (with or without HIV-2 infection)
and is not eligible for HAART
has received some antiretroviral prophylaxis during
pregnancy or delivery,
has an antenatal lymphocyte CD4 count above
the threshold for HAART initiation in pregnant
women according to the national recommendation
in each site
resides within the study area and is not intending
to move out of the area in the next year
gives consent to participate for her and her infantA baby will be excluded if:
 S/he presents clinical symptoms and/or biological
abnormalities equal to or greater than grade II of
the ANRS classification for adverse event on the day
of enrolment, with exceptions for haemoglobin
(baby excluded if Hb < 12 g/dL) and absolute
neutrophils count (baby excluded if neutrophils <
1200 cells/μL)
 S/he presents with serious congenital malformation(s) Her/his birth weight was < 2.0 kg
 The mother has participated in the ANRS 12174
trial for a previous pregnancy
 S/he and her/his mother are participating in another
clinical trial on the day of enrolment
Main study outcomes
Primary outcome measures
 Acquisition of HIV-1 (as assessed by HIV-1 DNA
PCR) between day 7 and 50 weeks of age.
Secondary outcome measures
 Severe adverse events (SAE) grade III or IV
possibly-related or with undetermined relation to
the study drug (according to ANRS SAE reporting
procedures), up to 50 weeks.
 In vitro HIV-1 resistance to antiretrovirals in infants
who will get infected with HIV-1 during the study
 Growth, i.e. length and weight up to 50 weeks of age
 HIV-1-free survival from day 7 until 50 weeks
(event: infant death or acquisition of HIV-1
infection in infants)
HIV acquisition is defined as follows:
During the course of the trial HIV-1 infection will be
established if HIV-1 DNA is detected in blood (detection
threshold of 150 viral copies/mL). All first positive HIV-
1 DNA PCR will be confirmed by a second test on
another sample taken 2 to 5 days later. If the second
test is negative, then the child will be considered HIV-1
uninfected for this study visit.
At enrolment (day 7) In order to ensure that infants
infected with HIV-1 at week 6 (or at first follow-up visit
if week 6 visit is missed) were not already infected at day
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dried blood spots (DBS) collected at day 7 using both a
Roche-Amplicor HIV-1 DNA PCR and a real time HIV-
1 RNA PCR (Figure 1). In case of a positive result with
at least one of the latter tests, the child will be consid-
ered HIV-1 infected at day 7 and therefore excluded
from the trial. This situation is expected to occur for
very few children.
Randomisation and stratification
Infants fulfilling the inclusion criteria will be randomised
on day 7 (+/− 2 days). Randomisation will be stratified
by country using permuted blocks of randomly varying
sizes 4 and 6. The eligible infants will be allocated to
one of two arms: LPV/r (twice daily) or Lamivudine
(twice daily) according to a 1:1 ratio. All randomisation
lists will be prepared (and kept) by an independent sta-
tistician in Montpellier, as well as by the data monitoring
committee (DMC) statistician.
Screening, Follow-up visits and outcome measurements
Antenatal screening (screening 1)
All antenatal clinics where the women will be screened
benefit from a PMTCT programme including routine
counselling and HIV testing. All HIV-infected pregnant
women attending these ANCs with a gestation period
between 28 and 40 weeks will be targeted for the first
screening visit. After comprehensive counselling on
infant feeding, mothers intending to breastfeed will be
briefly informed about the study and invited to attend
the first screening visit. After informed consent for this
visit, women will be offered a CD4 cell count and clin-
ical assessment (HIV-1 disease staging and investigation
for opportunistic infections). All HIV-1-infected women
and their babies will access PMTCT perinatal prophy-
laxis according to national guidelines [23]. Pregnant
women will be encouraged to deliver at a maternity
clinic. Pregnant women who require ART according to
existing guidelines [23] will be referred to national ART
access programmes in order to receive HAART for the
remainder of the pregnancy, through delivery and con-
tinued life-long. She and her infant will not be eligible
for the trial.
Post-natal screening (screening 2)
The post-natal screening will be carried out from 1 to
6 days after delivery. The baby will be tested for HIV-1
infection using a real-time PCR DNA assay, and for bio-
logical abnormalities (full blood count, ALAT/ASAT,
serum-creatinine). Finally, the study physician will assess
the baby for clinical exclusion criteria. If these clinical
criteria are met, the baby will be referred to the refer-
ence paediatrician for appropriate care.Follow-up procedures
Systematic follow-up visits will be organised at week 2
and every 4 weeks until week 50 (final visit) (Figure 2),
with clinical examination, adverse event reporting, infant
length/weight, counselling on infant feeding and drug
adherence. The primary outcome (HIV-1 DNA) will be
measured at week 6, 14, 26, 38 and 50.
Mothers and babies will be followed by research/
clinic-based visits, and if needed, by community-based
visits. Children will be assigned to scheduled clinic visits
and mothers will be encouraged to come back to the re-
search site whenever they or their babies are sick.
In babies, adverse events will be searched for and
reported. Severe adverse events will be reported accord-
ing to the sponsor guidelines. Infant feeding practices
will be monitored using tools based on WHO guidelines
[24]. Weight and length will be measured twice based
on guidelines developed by the WHO and z-scores
calculated using the new WHO child growth standards
[25] and the free WHO program (http://www.who.int/
childgrowth/training/en/). The intervention will be
stopped in children shown to be HIV-1-infected in order
to reduce the period of unnecessary exposure to LPV/r
or Lamivudine mono-prophylaxis and risk of emergence
of resistant viral populations to a minimum. At 50 weeks
of age, a final real time DNA PCR test will be done on
all babies, in order to detect late HIV-1 transmission
due to prolonged or resumed BF. Child survival will be
assessed at 38 weeks and at 50 weeks of age. Hospital
records and verbal autopsy will be used to measure over-
all and cause-specific infant mortality. Morbidity will
be measured by recall within the last week of the visit,
in-between visits and hospitalisations since last visit.
Study treatment
The study treatments will be administered using com-
mercial syrup formulations of lopinavir/ritonavir (80/
20 mg/mL) or lamivudine (10 mg/mL). Study drug
bottles of LPV/r and Lamivudine will be masked by
study labels.
Lopinavir/ritonavir (80/20 mg/mL) will be given to the
baby twice daily as recommended in infants, with the
following scheme: 40/10 mg (0.5 mL) twice daily if 2-
4 kg and 80/20 mg (1 mL) twice daily if >4 kg. Similarly,
lamivudine will be given as follows: 7,5 mg (0,75 mL)
twice daily if 2-4 kg, 25 mg (2.5 mL) twice daily if 4-8 kg
and 50 mg (5 mL) twice daily if >8 kg. These dosages
were calculated on the basis of a pharmacokinetic study
of LPV/r in young infants done in Paris[21]. For Lami-
vudine, calculations were based on a pharmacokinetic
study carried out by Moodley et al. [26]. Infants whose
mothers need and initiate HAART during the trial will
be discontinued from the study medication in order to
avoid excessive intake of ART in babies due to high
Screening 1: 
Pregnant women with:  
  - HIV-1 infection post-VCT 
  - not eligible for HAART 
  - intention to breastfeed 
  - CD4 as per national guideline      
 (min. 350 cells/µL) 
  - Intention to participate 
  - Antenatal screening consent 
Infant feeding counselling 
Antenatal clinics, 
from week 28 of 
gestation 
Screening 2: 
Newborn: 
- HIV-1 DNA PCR 
- Biochemistry 
- Clinical examination 
Mother:  
- Screening 2 consent 
HIV infection with            
CD4 below 350: 
Routine national PMTCT 
No HIV infection: 
Regular ANC care 
Delivery with routine 
national PMTCT 
Study site, 
Day 1-6 
Maternity  
Study site, 
Counselling 
Newborn/Mother: 
Inclusion/exclusion criteria 
Follow-up:  
Infant: 
- HIV-1 infection (PCR) at  
  prior visits and / or 
- Adverse events 
Enrolment  
and Randomisation 
Not included:  
Regular postnatal care or 
paediatric referral if required 
Infected or severe adverse 
events: Withdrawn from  
study medication but 
followed for outcomes 
Study site, 
Follow-up visit 
Study site, 
D7  2 days 
Completion of follow-up 
Figure 2 ANRS 12174 PROMISE-PEP trial screening, enrolment and follow-up visits contents.
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the maternal HAART regimen will much decrease the
risk of HIV transmission through breast milk [9].
Study size
The primary outcome will be assessed using a superior-
ity analysis. We expect the risk of acquiring HIV-1 infec-
tion between day 7 and 50 weeks of age to rangebetween 3% and 5% in the lamivudine group, based on
the findings of the MITRA study which reported a trans-
mission of 1.2% (95%CI: 0 to 2.4) between 6 weeks and
6 months and association between CD4 count and risk of
transmission observed in the VTS study [2]. This range
of 3 to 5% accounts for population with CD4 count
> 350 cells/μl and additional HIV transmission between
day 7 and week 6, and between 6 months and 50 weeks.
Nagot et al. BMC Infectious Diseases 2012, 12:246 Page 7 of 11
http://www.biomedcentral.com/1471-2334/12/246Considering its higher anti-HIV-1 activity, we expect a
higher efficacy of LPV/r, ranging from 1 to 2.5%, which
would be considered as a clinically relevant difference
compared with the lamivudine arm.
Table 1 displays different scenarios, based on a com-
parison of proportions with 80% power, a two-sided
alpha error of 5% and 10% lost to follow-up.
Including 1,500 infants in the trial (750 in each arm)
would allow us to cover most scenarios under the above
hypotheses.
Data analysis
Analysis methods will follow the CONSORT guidelines
[28] (Figure 3) and recommendations of the GHENT
group related to the mother-to-child transmission stud-
ies [29,30] and breastfeeding patterns [31].
All tests will be two-sided. Descriptive results, efficacy
and safety estimates and their corresponding 95% CIs
will be presented. The statistical significance is set at
p < 0.05.
Provided there are no major differences of relative
transmission risk between sites, the stratified (site-
specific) randomisation will be adjusted for in the ana-
lyses. Moreover, potential confounders, such as maternalAssessed
Analysed  (n=  )
Excluded from analysis 
(give reasons) (n=  )
Lost to follow-up 
(give reasons) (n=  )
Discontinued intervention 
(give reasons) (n=  )
Allocated to intervention (n=  )
Received allocated intervention (n=  )
Did not receive allocated intervention 
(give reasons) (n=  )Al
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Figure 3 ANRS 12174 PROMISE-PEP trial, planned CONSORT patient fCD4 counts, will be considered for further adjustment if
they are imbalanced at baseline, according to thresholds
pre-defined in the plan of analysis.
Interim analysis
One interim analysis will be carried out by the DMC
when about half of the projected HIV-transmissions
have occurred. We will suggest that the DMC follows
the DAMOCLES group recommendations [27].
Primary analyses
Analyses for the primary endpoint will be undertaken on
an intention-to-treat basis.
– Uninfected drop-outs and deaths will be censored
at the last outcome measurement.
– Children of mothers initiating HAART during the
study will no longer receive the study intervention.
They will be followed up for all outcomes as the
other children and will not be censored in the
primary analysis.
– Children who stop breastfeeding for various reasons
(mother illness or death, etc.) will be withdrawn
from study drugs one week later. They will continue for eligibility (n=  )
Excluded  (n=   )
Not meeting inclusion criteria (n=  )  
Declined to participate (n=  )
Other reasons (n=  )
Lost to follow-up 
(give reasons) (n=  )
Discontinued intervention 
(give reasons) (n=  )
Allocated to intervention (n=  )
Received allocated intervention (n=  )
Did not receive allocated intervention 
(give reasons) (n=  )
Analysed  (n=  )
Excluded from analysis 
(give reasons) (n=  )
omized (n=  )
low chart.
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in the primary analysis.
Primary endpoint The main endpoint is acquisition of
HIV-1 (as assessed by HIV-1 DNA PCR) between day 7
and 50 weeks of age, as defined previously.
The primary endpoint will be analysed using a time to
event approach. HIV-1 infections occurring between day
7 and week 50 will be compared between the two groups
of treatment using proportional hazard modelling with
hazard ratio and its 95% CI adjusted for site and any
confounders.
Relative treatment efficacy will be calculated as 100 ×
(1-HR) where HR is the hazard ratio of HIV-1 trans-
mission in the LPV/r group compared to the Lamivu-
dine group.
The effect size will also be expressed as the absolute
difference between risks with its 95% confidence inter-
val. The reduction in the number of patients who need
to be treated when given LPV/r compared to when given
Lamivudine to prevent HIV-1 infection in one infant will
be computed [32].
Secondary analyses
If LPV/r is not demonstrated to be superior to Lamivu-
dine in the primary analysis, we will conduct a non-
inferiority analysis of the primary outcome.
This analysis is supported by the expectancy of a bet-
ter resistance profile of LPV/r compared with Lamivu-
dine. A 95% confidence interval (adjusted for interim
analyses) for the hazard ratio of the primary efficacy out-
come will be constructed. The upper boundary for the
non inferiority is set at < 1.2, as we believe that any fur-
ther reduced efficacy would have important public
health consequences.
We will also carry out per protocol analyses for this
non-inferiority analysis. The conclusion will be drawn
from both the intention to treat and the per protocol
analyses.
Under the closed-testing procedure with sequential
testing of the superiority and non-inferiority analyses,
the overall 2-sided type 1 error is maintained at 5%.
Laboratory assays
All biological specimens will be analysed and stored at
each study site.
Paediatric HIV-1 infection will be diagnosed at each
site on Dried Blood Spots (DBS) by means of real-time
PCR, using a commercial kit (Generic HIV Charge
Virale, Biocentric, France) [33]. When necessary (see
Figure 1), a commercial real time RNA PCR (Generic
HIV Charge Virale, Biocentric, France) as well as
another commercial DNA PCR test (Roche Amplicor)
will be used in the coordinating laboratory (Montpellier).The real-time PCR technique is implemented with the
support of well-validated, standardised protocols designed
by a working group of the French National Agency for
Research on AIDS and Viral Hepatitis (ANRS) [34]. It is
well adapted to the use of DBS collected on filter paper,
an ideal tool for early paediatric HIV-1 diagnosis [35].
Maternal HIV-1 antibody detection will be performed
by ELISA and/or rapid tests, according to each site’s
national optimised algorithms [36]. Maternal plasma
HIV-1 RNA quantification (“viral load”) will be mea-
sured by means of a commercially available real time
RNA PCR test (Generic HIV Charge Virale, Biocentric,
France) [33]. CD4 counts will be performed by flow
cytometry. Haematological and biochemical assays will
be performed on babies' plasma samples by means of
already available automated procedures at the site labora-
tories. These tests will be carried out for safety mon-
itoring, and will include full blood counts and blood
concentration of liver enzymes. In addition, plasma LPV/r
and Lamivudine will be detected in blood at weeks 6 and
38 by high pressure liquid chromatography (HPLC) (JM
Tréluyer, Saint-Vincent de Paul Hospital, Paris).
HIV resistance mutations to antiretrovirals will be
identified by sequencing of the pol genes.
Laboratory and quality control procedures will follow
WHO Good Laboratory Practice Guidelines [37].
HIV-1 serology, CD4 counts, and haematology/bio-
chemistry assays will be submitted to a stringent quality
assessment programme, to an international external
quality control programme and to intensive GLP train-
ing addressed to the laboratory personnel in all 4 sites.
Training, technology transfer and standardisation
Real time PCR technology transfer and training will be
implemented in all 4 sites with implementation of a qual-
ity assessment and quality control programme from the
Montpellier team and the ANRS AC11 medical virology
group. Ongoing training and monitoring will occur dur-
ing the full duration of the follow-up period of the study.
Likewise, initial and ongoing training and standardization
will be undertaken to ensure adequate reproducibility and
validity of anthropometric measurements.
Human subjects considerations
The study will be conducted in accordance with the
sponsor’s (ANRS) Charter of Ethics, with the Inter-
national Conference on Harmonisation (ICH) guidelines
for good clinical practice and with the Medicines Con-
trol Council guidelines for good clinical practice in the
conduct of clinical trials in human participants in South
Africa. The study protocol has been submitted to and
approved by the Ethical Committee for Health Research
in Burkina Faso, the Biomedical research Ethics Com-
mittee in Zambia, the Uganda National Council for
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ethical committees, the Medicines Control Council in
South Africa and the Regional Committee for Medical
research Ethics of Norway.
Written informed consent and assent will be obtained
in vernacular language from the mother of participating
mother-infant pairs. The informed consent process
will be implemented with an independent third person
(the ‘witness’) for illiterate mothers or when translation
is required. This witness will sign the consent form
together with the mother and the investigator.
Mothers requiring HAART during pregnancy and
infants diagnosed with HIV at screening or during the
trial will be referred to the study-related HIV care unit
for prompt HIV management according to local guide-
lines. In particular, infants will be treated with HAART
as soon as HIV infection is diagnosed.
Discussion
This trial will compare the efficacy and safety of infant
lopinavir/ritonavir versus lamivudine to reduce HIV-1
transmission during breastfeeding. Although NVP was
studied more extensively than Lamivudine for PEP pur-
poses, we decided to use the latter drug for the com-
parative arm as we expect a similar efficacy as NVP
(according to the MITRA study) with similar adverse
events but with less detrimental genetic barrier profile.
Indeed, we believe that the ‘cost’ of using NVP for PEP
during breastfeeding (i.e. to deprive infants who will fail
PEP of a major class of ART for their HIV treatment) is
too high to recommend this drug for prevention of post-
natal HIV transmission.
Active clinical and biologic follow up of infants and
systematic report of potential effects will be organised
according to GCP and GLP international guidelines
for toxicity and adverse event management. Recently,
breastfed infants of HAART-treated mothers have been
shown to ingest sufficient amounts of ART by breast-
feeding to reach plasma therapeutic levels (at least for
NVP, AZT and 3TC) [22]. Therefore, in order to avoid
additional toxicity and overdosage of lamivudine or
LPV/r in babies (and because maternal HAART is most
likely to reduce postnatal HIV-1 transmission) our trial
will recruit only babies born of mothers not eligible for
HAART. Likewise, infants whose mothers need and ini-
tiate HAART during the trial will also be discontinued
from the study medication. Similar to post-exposure
prophylaxis, the study medication will continue one
week after cessation of breastfeeding (= last exposure of
HIV), after a maximum of 49 weeks of breastfeeding.
This extended period of study treatment is justified as it
parallels standard post-exposure prophylaxis.
This study will provide a new evidence-based interven-
tion to support HIV-1-infected women not eligible forHAART to safely breastfeed their babies, thus counter-
acting the existing contradiction between optimal infant
feeding and PMTCT through breast milk. Assuming a
full coverage and 60% efficacy of the intervention, about
120,000 cases of post-natal HIV-1 transmission could be
averted per year in Africa. In addition, a prolonged
breastfeeding period of HIV-infected mothers will reduce
stigmatisation of infant feeding patterns and disclosure
of maternal HIV status [38], and will improve health
outcomes in infants born to HIV-infected mothers. By
extension, this intervention will also contribute to
promote breastfeeding in the communities beyond HIV-
infected women [8,39]. Optimised breastfeeding promo-
tion has the potential of annually averting 1.3 million
child deaths globally, if universally implemented.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
TT and PV designed the study. All authors contributed to the study design
and the protocol writing. NN drafted this manuscript and all co-authors
provided constructive comments. All authors read and approved the final
manuscript.
Authors' information
PROMISE-PEP Study group
University of Montpellier 1 (France): Philippe Van de Perre (principal
investigator), Nicolas Nagot (project leader), Roselyne Vallo (central data
manager), Valerie Marechal (central lab coordinator), Dorine Neveu
(statistician), Vincent Foulongne (virologist), Michel Segondy (virologist),
Roxanne Schaub (statistician)
University of Paris V (France): Stephane Blanche (paediatrician), Jean-Marc
Treluyer (pharmacologist), Deborah Hirt (modeler)
Makerere University (Uganda): James K Tumwine (Site PI), Charles Karamagi
(Investigator), Philippa Musoke (Investigator), Grace Ndeezi (Invesitgator),
Proscovia M Mugaba, Mary Kwagala (Coordinator), Joan Murungi (Clinician),
Hawa Nabuuma Muweesi (Lab Coordinator), Evelyn Ninsiima (Lab
Technologist), Simon Baryeija (Pharmacist)
University of Ouagadougou (Burkina Faso): Nicolas Meda (site principal
investigator), Rasmata Ouédraogo (biologist), Diarra Yé (paediatrician), Eric
Somé (site trial coordinator), Hugues A. Traoré (site clinical study monitor),
Christelle Nadembega (site biological study monitor), Justin Konaté (assistant
of biological study monitor), Arsène Zongo (site pharmacist), Abass
Ouédraogo (pharmacist assistant), Désiré Néboua (study physician), Aissatou
Bélemviré (study physician), Armel Bambara (site data manager), Justine
Boncoungou (social worker), Danielle Zoungrana (social worker)
University of Western Cape (South Africa): Cheryl Nikodem (Site principal
investigator), Kim Harper (Site Co-principal investigator), Debra Jackson
(Co-investigator), David Sanders (Country Principal Investigator), Mandisa
Singata (project leader), Amwe Sunday (Research clinician),
Collins Okegbe-Eze (Research clinician), Xoliswa Williams (Research clinician),
Nolundi Mshweshwe (Research clinician), Vatiswa Henge (Pharmacist),
Fikiswa Gomba (Breastfeeding counsellor), Lada Nikodem (Data manager),
Oswell Khondowe (Trainer)
University of Zambia (Zambia): Chipepo Kankasa (Site principal investigator),
Mwiya Mwiya (site trial coordinator), Mildreed Lusaka (UTH Site Coordinator),
Mary Chizyuka (UTH Site co-Coordinator), Mary Phiri (Chawama Site
Coordinator), Billies Imakando (Chawama Site Coordinator), Mwenechanya
Musaku (study physician), Monica Kapasa (study physician), David Rutagwera
(Laboratory Coordinator), Ngondwe Clement (co-Laboratory Coordinator),
Hilton Mwila Mwaba (lab scientist), (lab scientist), Japhet Matoba (Laboratory
Scientist), Hilton Mwaba (Laboratory Technician), Chafye Siumita
(Adminstrator/Data Clerk), Katai Chola (Data Manager), Patricia Mwamutanda
(Pharmacist).
Nagot et al. BMC Infectious Diseases 2012, 12:246 Page 10 of 11
http://www.biomedcentral.com/1471-2334/12/246University of Bergen (Norway): Thorkild Tylleskar (Site principal investigator),
Halvor Sommerfelt (investigator), Ingunn Engebretsen (investigator), Jørn
Klungsøyr (investigator), Jan van den Broeck (investigator).
Funding
Sponsor: France National Agency for Research on AIDS & Hepatitis (ANRS)
Other funding bodies: European Developing Countries Clinical Trials
Partnership (EDCTP) and Research Council of Norway
In kind contribution: Universities of: Western Cape (South Africa), Zambia,
Makerere (Uganda), Ouagadougou (Burkina Faso), Montpellier 1 (France),
Paris V (France) and Bergen (Norway).
Acknowledgements
Makerere University: we thank Prof. Peter Mugyenyi Director of the JCRC,
Cissy Kityo, Sitefano Tugume, James Nkalubo, Mary Abwola, Daniel Luzinda
and all JCRC staff for their support. To Benon Wanume, the Mbale Hospital
Medical Superintendent, Robert Byamugisha and all the staff of Mbale
Hospital, the PROMISE PEP, and the health centres in the region we are very
grateful for your cooperation and participation.
We wish to thank Claire Rekacewicz, Brigitte Bazin and Jean-François
Delfraissy from ANRS for their constant support and encouragements, as well
as all health authorities from the four African sites who facilitated the
initiation of the trial.
Author details
1INSERM U 1058 and CHU, Montpellier, France. 2Universite Montpellier 1,
Montpellier, France. 3Département de Bactériologie-Virologie et Département
d’Information Médicale, CHU Montpellier, Montpellier, France. 4Department
of Paediatrics and Child Health, University of Zambia, School of Medicine,
Lusaka, Zambia. 5Centre of International Research for Health, Faculty of
Health Sciences, University of Ouagadougou and Centre MURAZ,
Bobo-Dioulasso, Burkina Faso. 6University of Western Cape, Cape Town,
South Africa. 7Department of Paediatrics and Child Health, College of Health
Sciences, School of Medicine Makerere University, Kampala, Uganda. 8Centre
for International Health, University of Bergen, Bergen, Norway. 9Division of
Infectious Disease Control, Norwegian Institute of Public Health, Oslo,
Norway.
Received: 18 August 2011 Accepted: 30 August 2012
Published: 6 October 2012
References
1. Dunn DT, Newell ML, Ades AE, Peckham CS: Risk of human
immunodeficiency virus type 1 transmission through breastfeeding.
Lancet 1992, 340(8819):585–588.
2. Coovadia HM, Rollins NC, Bland RM, Little K, Coutsoudis A, Bennish ML,
Newell ML: Mother-to-child transmission of HIV-1 infection during
exclusive breastfeeding in the first 6 months of life: an intervention
cohort study. Lancet 2007, 369(9567):1107–1116.
3. Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai WY, Coovadia HM: Method
of feeding and transmission of HIV-1 from mothers to children by
15 months of age: prospective cohort study from Durban, South Africa.
AIDS 2001, 15(3):379–387.
4. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM: Influence of
infant-feeding patterns on early mother-to-child transmission of HIV-1 in
Durban. South Africa: a prospective cohort study. South African Vitamin
A Study Group. Lancet 1999, 354(9177):471–476.
5. Iliff PJ, Piwoz EG, Tavengwa NV, Zunguza CD, Marinda ET, Nathoo KJ,
Moulton LH, Ward BJ, Humphrey JH: Early exclusive breastfeeding reduces
the risk of postnatal HIV-1 transmission and increases HIV-free survival.
AIDS 2005, 19(7):699–708.
6. Kuhn L, Stein Z, Susser M: Preventing mother-to-child HIV transmission in
the new millennium: the challenge of breast feeding. Paediatr Perinat
Epidemiol 2004, 18(1):10–16.
7. Homsy J, Moore D, Barasa A, Were W, Likicho C, Waiswa B, Downing R,
Malamba S, Tappero J, Mermin J: Breastfeeding, mother-to-child HIV
transmission, and mortality among infants born to HIV-Infected women
on highly active antiretroviral therapy in rural Uganda. J Acquir Immune
Defic Syndr 2010, 53(1):28–35.
8. Black RE, Morris SS, Bryce J: Where and why are 10 million children dying
every year? Lancet 2003, 361(9376):2226–2234.9. Kesho Bora Study Group: Triple antiretroviral compared with zidovudine
and single-dose nevirapine prophylaxis during pregnancy and
breastfeeding for prevention of mother-to-child transmission of HIV-1
(Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011,
11:171–I.
10. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J,
Moyo S, Thior I, McIntosh K, et al: Antiretroviral regimens in pregnancy
and breast-feeding in Botswana. New Engl J Med 2010, 362(24):2282–2294.
11. Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, Bhore AV,
Bhosale R, Varadhrajan V, Gupte N, et al: Extended-dose nevirapine to
6 weeks of age for infants to prevent HIV transmission via breastfeeding
in Ethiopia, India, and Uganda: an analysis of three randomised
controlled trials. Lancet 2008, 372(9635):300–313.
12. Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, Li Q,
Mipando L, Nkanaunena K, Mebrahtu T, Bulterys M, et al: Extended
antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
N Engl J Med 2008, 359(2):119–129.
13. Kilewo C, Karlsson K, Massawe A, Lyamuya E, Swai A, Mhalu F, Biberfeld G:
Prevention of mother-to-child transmission of HIV-1 through breast-
feeding by treating infants prophylactically with lamivudine in Dar es
Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008,
48(3):315–323.
14. WHO: HIV and infant feeding: Revised Principles and Recommendations. Rapid
Advice. Geneva: World Health Organisation; 2009:28.
15. Giaquinto C, Rampon O, Penazzato M, Fregonese F, De Rossi A, D’Elia R:
Nucleoside and nucleotide reverse transcriptase inhibitors in children.
Clin Drug Investig 2007, 27(8):509–531.
16. Pacifici GM: Pharmacokinetics of antivirals in neonate. Early Hum Dev
2005, 81(9):773–780.
17. Kaplan SS, Hicks CB: Lopinavir/ritonavir in the treatment of human
immunodeficiency virus infection. Expert Opin Pharmacother 2005,
6(9):1573–1585.
18. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA,
Jean-Philippe P, McIntyre JA: Early antiretroviral therapy and mortality
among HIV-infected infants. N Engl J Med 2008, 359(21):2233–2244.
19. Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH,
Chen J, Palumbo P, Serchuck L, Smith E, et al: Pharmacokinetics, safety and
efficacy of lopinavir/ritonavir in infants less than 6 months of age:
24 week results. AIDS 2008, 22(2):249–255.
20. Chadwick EG, Pinto J, Yogev R, Alvero CG, Hughes MD, Palumbo P,
Robbins B, Hazra R, Serchuck L, Heckman BE, et al: Early initiation of
lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics
and 24-week safety and efficacy. Pediatr Infect Dis J 2009, 28(3):215–219.
21. Urien S, Firtion G, Anderson S, Rey E: Lopinavir/Ritonavir Population
Pharmacokinetics in Neonates. In XVIth Conference on retroviruses and
opportunistic infections. Montreal: Abs #944; 2009.
22. Shapiro RL, Holland DT, Capparelli E, Lockman S, Thior I, Wester C,
Stevens L, Peter T, Essex M, Connor JD, et al: Antiretroviral concentrations
in breast-feeding infants of women in Botswana receiving antiretroviral
treatment. J Infect Dis 2005, 192(5):720–727.
23. World Health Organization: Antiretroviral drugs for treating pregnant women
and preventing HIV infection in infants in ressource-limited settings. Towards
universal access. Recommendations for a public health approach. Geneva:
WHO; 2006. Revisions.
24. World Health Organization: Breastfeeding and replacement feeding practices
in the context of mother to child transmission of HIV. An assessment tool for
research. Geneva: WHO; 2001.
25. World Health Organization: United Nations Children’s Fund. WHO child growth
standards and the identification of severe acute malnutrition in infants and
children. Geneva: WHO; 2009.
26. Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R,
Goodwin C, Harrigan PR, Moore KHP, Stone C, et al: Pharmacokinetics and
antiretroviral activity of lamivudine alone or when coadministered with
zidovudine in human immunodeficiency virus type 1–infected pregnant
women and their offspring. J Infect Dis 1998, 178:1327–33.
27. DAMOCLES Study Group: A proposed charter for clinical trial data
monitoring committees: helping them to do their job well. Lancet 2005,
365(9460):711–722.
28. Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. PLoS Med,
7(3):e1000251.
Nagot et al. BMC Infectious Diseases 2012, 12:246 Page 11 of 11
http://www.biomedcentral.com/1471-2334/12/24629. Alioum A, Cortina-Borja M, Dabis F, Dequae-Merchadou L, Haverkamp G,
Hughes J, Karon J, Leroy V, Newell ML, Richardson BA, et al: Estimating the
efficacy of interventions to prevent mother-to-child transmission of
human immunodeficiency virus in breastfeeding populations: comparing
statistical methods. Am J Epidemiol 2003, 158(6):596–605.
30. Alioum A, Dabis F, Dequae-Merchadou L, Haverkamp G, Hudgens M,
Hughes J, Karon J, Leroy V, Newell ML, Richardson B, et al: Estimating the
efficacy of interventions to prevent mother-to-child transmission of HIV
in breast-feeding populations: development of a consensus
methodology. Stat Med 2001, 20(23):3539–3556.
31. Gaillard P, Piwoz E, Farley TM: Collection of standardized information on
infant feeding in the context of mother-to-child transmission of HIV.
Stat Med 2001, 20(23):3525–3537.
32. Guyatt GH, Sackett DL, Cook DJ: Users’ guides to the medical literature.
II. How to use an article about therapy or prevention. B. What were the
results and will they help me in caring for my patients? Evidence-Based
Medicine Working Group. JAMA 1994, 271(1):59–63.
33. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, Danel C,
Anglaret X, Leroy V, Msellati P, et al: Transfer and evaluation of an
automated, low-cost real-time reverse transcription-PCR test for
diagnosis and monitoring of human immunodeficiency virus type 1
infection in a West African resource-limited setting. J Clin Microbiol 2005,
43(6):2709–2717.
34. Schvachsa N, Turk G, Burgard M, Dilernia D, Carobene M, Pippo M,
Gomez-Carrillo M, Rouzioux C, Salomon H: Examination of real-time PCR
for HIV-1 RNA and DNA quantitation in patients infected with HIV-1 BF
intersubtype recombinant variants. J Virol Methods 2007, 140(1–2):222–227.
35. Avettant-Fenoel V, Chaix M, Blanche S, Burgard M, Warszawski JCR: Early
diagnosis of HIV-1 infection in newborns, in the context of prevention of
mother-to-child transmission with HAART (Perinatal Cohort ANRS Co 01).
In Dominique Dormont International Conference, Maternal Chronic Viral
Infections Transmitted to the Infants: from mechanisms to Prevention and
Care. Paris; 2007.
36. Meda N, Gautier-Charpentier L, Soudre RB, Dahourou H, Ouedraogo-Traore
R, Ouangre A, Bambara A, Kpozehouen A, Sanou H, Valea D, et al:
Serological diagnosis of human immuno-deficiency virus in Burkina
Faso: reliable, practical strategies using less expensive commercial test
kits. Bull World Health Organ 1999, 77(9):731–739.
37. UNDP/World Bank/WHO: Handbook Good Laboratory Practise. Geneva; 2001.
38. Doherty T, Chopra M, Nkonki L, Jackson D, Greiner T: Effect of the HIV
epidemic on infant feeding in South Africa: “When they see me coming
with the tins they laugh at me”. Bull World Health Organ 2006, 84(2):90–96.
39. Tylleskar T, Jackson D, Meda N, Engebretsen IM, Chopra M, Diallo AH,
Doherty T, Ekstrom EC, Fadnes LT, Goga A, et al: Exclusive breastfeeding
promotion by peer counsellors in sub-Saharan Africa (PROMISE-EBF): a
cluster-randomised trial. Lancet 2011, 378(9789):420–427.
doi:10.1186/1471-2334-12-246
Cite this article as: Nagot et al.: Lopinavir/Ritonavir versus Lamivudine
peri-exposure prophylaxis to prevent HIV-1 transmission by
breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174. BMC
Infectious Diseases 2012 12:246.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
